我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Sanyou Bio and Baiyunshan Xihe signed a strategic agreement to co-develop novel radiopharmaceuticals and radiodiagnostic products for precision oncology. - The partnership integrates Sanyou's AI-driven antibody discovery platform (AI-STAL, with over 11 trillion library capacity) with Baiyunshan Xihe's nuclear medicine value chain. - Baiyunshan Xihe brings standardized production technologies for medical radionuclides including Gallium-68, Zirconium-89, Copper-64, and Rhenium-186. - The collaboration aims to build an end-to-end innovation chain from AI-driven molecular discovery through radionuclide labeling to clinical translation.
